Biomarin Pharmaceutical (BMRN) Net Margin (2009 - 2026)

Biomarin Pharmaceutical has disclosed Net Margin across 18 years of filings, most recently posting 13.77% for Q1 2026.

• Quarterly Net Margin fell 1115.0% year-over-year to 13.77% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.29% (down 947.0% YoY) and the FY2025 annual result came in at 10.83%, down 413.0% from the prior year.
• Net Margin rose to 13.77% in Q1 2026, from 5.33% in the prior quarter.
• Over five years, Net Margin peaked at 29.14% in Q2 2025 and troughed at 5.33% in Q4 2025.
• A 5-year average of 10.2% and a median of 9.41% in 2023 frame the typical range for Net Margin.
• Annual changes were most pronounced in 2022 — Net Margin soared 1968 bps — and 2025, when it tumbled 2204 bps.
• Tracing BMRN's Net Margin over 5 years: stood at 0.05% in 2022, then surged by 6907 bps to 3.15% in 2023, then surged by 430 bps to 16.72% in 2024, then plunged by 132 bps to 5.33% in 2025, then surged by 359 bps to 13.77% in 2026.
• Business Quant data shows BMRN's Net Margin at 13.77% in Q1 2026, 5.33% in Q4 2025, and 3.96% in Q3 2025.